Design and analysis of oncology clinical trials

Oncology: An Evidence-Based Approach

Volumn , Issue , 2006, Pages 112-126

  Dignam, James J ^a   Karrison, Theodore G ^a   Bryant, John ^b  

^a University of Chicago   (United States)

^b NSABP Foundation Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66249094615     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-31056-8_8     Document Type: Chapter

References (79)

1. Crowley J (ed). Handbook of Statistics in Clinical Oncology. New York: Dekker, 2001.
2. Green S, Benedetti J, Crowley JJ. Clinical Trials in Oncology, 2nd ed. Boca Raton: Chapman & Hall/CRC, 2003.
3. Halpern SD, Karlawish JHT, Berlin JA. The continuing unethical conduct of underpowered clinical trials. JAMA 2002;288:358-362.
4. Piantadosi S. Clinical Trials: A Methodologic Perspective. New York: Wiley, 1997.
5. Iyer L, Das S, Janisch L, et al. UGT1A1-28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002;2:43-47.
6. Leventhal BG, Wittes RE. Phase I trials. In: Leventhal BG, Wittes RE (eds). Research Methods in Clinical Oncology. New York: Raven Press, 1988:41-59.
7. Von Hoff DD, Rozencweig M, Muggia FM. Variation in toxicities of anticancer drugs in children and adults. Clin Pharmacol Ther 1977;21:121.
8. Von Hoff DD, Kuhn J, Clark GM. Design and conduct of phase I trials. In: Buyse ME, Staquet MJ, Sylvester RJ (eds). Cancer Clinical Trials, Methods and Practice. Oxford: Oxford University Press, 1984:210-220.
9. Storer B. Design and analysis of phase I clinical trials. Biometrics 1989;45:925-937.
10. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-1161.
11. Carter SK. Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy programme of the National Cancer Institute. In: Staquet MJ (ed). The Design of Clinical Trials in Cancer Therapy. Brussels: Editions Scientique Europe, 1973:242-389.
12. Simon R, Freidlin B, Rubinstein I, et al. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 1997;89:1138-1147.
13. Legedza AT, Ibrahim J. Longitudinal design for phase I clinical trials using the continual reassessment method. Control Clin Trials 2000;21:574-588.
14. Storer B. Small-sample confidence sets for the MTD in a phase I clinical trial. Biometrics 1993;49:1117-1125.
15. Korn EL, Midthune D, Chen TT, et al. A comparison of two phase I trial designs. Stat Med 1994;13:1799-1806.
16. Ivanova A, Montazer-Haghighi A, Mohanty SG, Durham SD. Improved up-and-down designs for phase I trials. Stat Med 2003; 22:69-82.
17. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990;48:853-862.
18. Shen LZ, O'Quigley. Consistency of continual reassessment method in dose finding studies. Biometrika 1996;83:395-406.
19. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 1994;4: 147-164.
20. Leung DH, Wang Y. Isotonic designs for phase I trials. Control Clin Trials 2001;22:126-138.
21. Cheung YK, Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 2000;56:1177-1182.
22. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
23. Chen TT, Chute JP, Feigal E, et al. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000;92:1601-1607.
24. Buyse M, Thirion P, Carlson RW, et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-378.
25. Moertel CG. Improving the efficiency of clinical trials: a medical perspective. Stat Med 1984;3:455-465.
26. Fleming TR. One sample multiple testing procedures for phase II clinical trials. Biometrics 1982;38:143-151.
27. Gehan E. The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961;13:346-353.
28. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
29. Jung S-H, Carey M, Kim K. Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials 2001;22: 367-372.
30. Ensign LG, Gehan E, Kamen DS, et al. An optimal three-stage design for phase II clinical trials. Stat Med 1994;13:1727-1736.
31. Chen TT. Optimal three-stage designs for phase II cancer clinical trials. Stat Med 1997;16:2701-2711.
32. Panageas KS, Smith A, Gonen M, et al. An optimal two-stage phase II design utilizing complete and partial response information separately. Control Clin Trials 2002;23:367-379.
33. Lin SP, Chen T. Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses. Comm Stat A-Theory Methods 2000;29:923-940.
34. Conaway MR, Petroni GR. Bivariate sequential designs for phase II trials. Biometrics 1995;51:656-664.
35. Bryant J, Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995;51: 1372-1383.
36. Conaway MR, Petroni GR. Designs for phase II trials allowing for trade-off between response and toxicity. Biometrics 1996;52: 1375-1386.
37. Berry DA. Decision analysis and Bayesian methods in clinical trials. In: Thall PF (ed). Recent Advances in Clinical Trial Design and Analysis. Boston: Kluwer, 1995:125-154.
38. Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics 1994;50:337-349.
39. Thall PF, Simon R, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med 1995;14:357-379.
40. Heitjan DF. Bayesian interim analysis of phase II cancer clinical trials. Stat Med 1997;16:1791-1802.
41. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985;69:1375-1381.
42. Liu PY, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. Biometrics 1993;49:391-398.
43. Estey EH, Thall PF. New designs for phase 2 clinical trials. Blood 2003;102:442-448.
44. Mick R, Crowley JJ, Carroll RJ. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 2000;21: 343-359.
45. Rosner GL, Stadler W, Ratain MJ. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 2002;20:4478-4484.
46. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19:265-272.
47. Gehan E. The evaluation of therapies: historical control studies. Stat Med 1984;3:315-324.
48. Hellman S, Hellman DS. Of mice but not men. Problems of the randomized clinical trial. N Engl J Med 1991;324:1585-1589.
49. Dupont WD. Randomized vs. historical clinical trials: Are the benefits worth the costs? Am J Epidemiol 1985;122:940-947.
50. Micciolo R, Valagussa P, Marubini E. The use of historical controls in breast cancer. An assessment in three consecutive trials. Control Clin Trials 1985;6:259-270.
51. Byar DP. Why databases should not replace randomized clinical trials. Biometrics 1980;36:337-342.
52. Freedman LS. Tables of the number of patients required in clinical trials using the log-rank test. Stat Med 1982;1:121-129.
53. Lachin JM, Foulkes MA. Evaluation of sample size and power for analysis of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986;42:507-519.
54. Lagakos E. Sample size based on the log-rank statistic in complex clinical trials. Biometrics 1988;44:229-241.
55. Shih JH. Sample size calculation for complex clinical trials with survival endpoints. Control Clin Trials 1995;16:395-407.
56. Ahnn S, Anderson SJ. Sample size determination in complex clinical trials comparing more than two groups for survival endpoints. Stat Med 1998;17:2525-2534.
57. Therneau TM. How many stratification factors are "too many"to use in a randomization plan? Control Clin Trials 1993;14:98-108.
58. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-115.
59. Jennison C, Turnbull J. Group Sequential Methods with Applications to Clinical Trials. London: Chapman & Hall/CRC, 2000.
60. George SL, Li C, Berry D, et al. Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. Stat Med 1996;13:1313-1327.
61. Smith MA, Ungerleider RS, Korn EL, et al. Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. J Clin Oncol 1997;15: 2736-2743.
62. Gail MH. Eligibility exclusions, losses to follow-up, removal of randomized patients, and uncounted events in cancer clinical trials. Cancer Treat Rep 1985;69:1107-1113.
63. Redmond C, Fisher B, Wieand HS. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. Cancer Treat Rep 1983;67:519-526.
64. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
65. Mantel N. Evaluation of survival data and two rank order statistics in its consideration. Cancer Chemother Rep 1966;50: 163-170.
66. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Ser B 1972;34:187-220.
67. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily single-censored samples. Biometrika 1965;52:203-223.
68. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc A 1972;135:189-198.
69. Prentice RL. Linear rank tests with right censored data. Biometrika 1978;65:167-179.
70. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika 1982;69:553-566.
71. Parmar MK, Ungerleider RS, Simon R. Assessing whether to perform a confirmatory randomized clinical trial. J Natl Cancer Inst 1996;88:1645-1651.
72. Berry DA. When is a confirmatory randomized clinical trial needed? (editorial) J Natl Cancer Inst 1996;88:1606-1607.
73. Moher D, Schulz KF, Altman D; CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.
74. Rockette HE, Redmond CK. Limitations and advantages of meta-analysis in clinical trials. Recent Results Cancer Res 1988; 111:99-104.
75. Pignon JP, Hill C. Meta-analyses of randomized clinical trials in oncology. Lancet Oncol 2001;2:475-482.
76. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-1467.
77. Parmar MKB, Spiegelhalter DJ, Freedman LS, et al. The CHART trials: Bayesian design and monitoring in practice. Stat Med 1994;13:1297-1312.
78. Stenning SP, Parmar MKB. Designing randomized trials: both large and small trials are needed. Ann Oncol 2002;13:131-138.
79. Parmar MKB, Griffiths GO, Spiegelhalter DJ, et al. Monitoring of large randomized clinical trials: a new approach with Bayesian methods. Lancet 2001;358:375-381.